Backed by Mercia Fund Management, a third of the funding comes from the TSB Smart Award.

Oxford Genetics, a biotech specialising in synthetic DNA, has secured £300,000 ($507,000) in funding. Previous investor Mercia Fund Management has invested £200,000 ($338,000), while a further £100,000 ($169,000) are from the TSB Smart Award, which recognises excellency in pharmacy.

The company previously secured £150,000 ($256,000) from Mercia in June 2013.

Oxford Genetics is based on research by Len Seymour, professor at Oxford University’s Department of Oncology, and Ryan Cawood. Its lead product is SnapFast, which allows a simplified purchase of…